JP7789483B2 - Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 - Google Patents

Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少

Info

Publication number
JP7789483B2
JP7789483B2 JP2020523705A JP2020523705A JP7789483B2 JP 7789483 B2 JP7789483 B2 JP 7789483B2 JP 2020523705 A JP2020523705 A JP 2020523705A JP 2020523705 A JP2020523705 A JP 2020523705A JP 7789483 B2 JP7789483 B2 JP 7789483B2
Authority
JP
Japan
Prior art keywords
individual
scd163
composition
avacopan
urinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020523705A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021501159A (ja
JP2021501159A5 (https=
Inventor
トン チュン
ジェイ．シャール トーマス
ベッカー ペトラス
Original Assignee
ケモセントリックス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケモセントリックス，インコーポレイティド filed Critical ケモセントリックス，インコーポレイティド
Publication of JP2021501159A publication Critical patent/JP2021501159A/ja
Publication of JP2021501159A5 publication Critical patent/JP2021501159A5/ja
Priority to JP2023112051A priority Critical patent/JP2023133317A/ja
Application granted granted Critical
Publication of JP7789483B2 publication Critical patent/JP7789483B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020523705A 2017-10-31 2018-10-30 Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少 Active JP7789483B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023112051A JP2023133317A (ja) 2017-10-31 2023-07-07 Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762579716P 2017-10-31 2017-10-31
US62/579,716 2017-10-31
PCT/US2018/058134 WO2019089534A1 (en) 2017-10-31 2018-10-30 C5aR INHIBITOR REDUCTION OF URINARY sCD163

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023112051A Division JP2023133317A (ja) 2017-10-31 2023-07-07 Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少

Publications (3)

Publication Number Publication Date
JP2021501159A JP2021501159A (ja) 2021-01-14
JP2021501159A5 JP2021501159A5 (https=) 2021-12-09
JP7789483B2 true JP7789483B2 (ja) 2025-12-22

Family

ID=66326509

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523705A Active JP7789483B2 (ja) 2017-10-31 2018-10-30 Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少
JP2023112051A Pending JP2023133317A (ja) 2017-10-31 2023-07-07 Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023112051A Pending JP2023133317A (ja) 2017-10-31 2023-07-07 Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少

Country Status (9)

Country Link
US (2) US20190134020A1 (https=)
EP (2) EP4671767A3 (https=)
JP (2) JP7789483B2 (https=)
KR (1) KR20200109297A (https=)
CN (1) CN111670185A (https=)
AR (1) AR113815A1 (https=)
AU (2) AU2018359237A1 (https=)
CA (1) CA3078732A1 (https=)
WO (1) WO2019089534A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801519A4 (en) 2018-06-07 2022-03-30 ChemoCentryx, Inc. DOSAGE AND EFFECTS OF C5A ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
SMT202400521T1 (it) 2018-11-30 2025-01-14 Chemocentryx Inc Formulazioni di capsula
CA3235574A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
CN114641288A (zh) 2019-11-08 2022-06-17 凯莫森特里克斯股份有限公司 补体成分C5a受体的无定形形式
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
WO2022093971A1 (en) * 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
EP4262800A4 (en) * 2020-12-21 2024-11-20 ChemoCentryx, Inc. TREATMENT OF C3 GLOMERULOPATHY WITH A C5A INHIBITOR
AU2022207985A1 (en) 2021-01-13 2023-07-06 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529647A (ja) 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
NZ730123A (en) 2014-09-29 2023-05-26 Chemocentryx Inc Processes and intermediates in the preparation of c5ar antagonists
WO2016166357A2 (en) * 2015-04-17 2016-10-20 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth, Near Dublin Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject
AU2017246228B2 (en) * 2016-04-04 2021-04-15 Chemocentryx, Inc. Soluble C5aR antagonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529647A (ja) 2010-06-24 2013-07-22 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J Am Soc Nephrol, 2016年, Vol.27, pp.2551-2553
J Am Soc Nephrol, 2016年, Vol.27, pp.2906-2916
J Am Soc Nephrol, 2017年09月, Vol.28, pp.2756-2767

Also Published As

Publication number Publication date
EP4671767A2 (en) 2025-12-31
CA3078732A1 (en) 2019-05-09
JP2021501159A (ja) 2021-01-14
KR20200109297A (ko) 2020-09-22
US20230105869A1 (en) 2023-04-06
AR113815A1 (es) 2020-06-17
EP4671767A3 (en) 2026-03-11
CN111670185A (zh) 2020-09-15
EP3704110A1 (en) 2020-09-09
AU2024202593A1 (en) 2024-05-09
JP2023133317A (ja) 2023-09-22
WO2019089534A1 (en) 2019-05-09
AU2018359237A1 (en) 2020-04-30
EP3704110A4 (en) 2021-08-04
US20190134020A1 (en) 2019-05-09
TW201922289A (zh) 2019-06-16

Similar Documents

Publication Publication Date Title
JP7789483B2 (ja) Ｃ５ａＲ阻害剤による尿中ｓＣＤ１６３の減少
JP7788814B2 (ja) Ｃ３腎症を処置する方法
JP7747614B2 (ja) Ｐｄ－ｌ１阻害剤としてのインダン
ES2969532T3 (es) 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico
EP4644380A1 (en) Pyridazine nlrp3 inhibitor compound, pharmaceutical composition, and preparation method therefor and use thereof
TW200815017A (en) Imidazoazephinone compounds
JP2022078194A (ja) 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン
JP2024526191A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
CN121487952A (zh) 一种pan-RAS抑制剂化合物
TWI913215B (zh) 減少尿液sCD163之C5aR抑制劑
CN1527713A (zh) 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法
HK40079875A (en) Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN121487942A (zh) Irak抑制剂游离碱、盐及其多晶型
HK1262045B (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK1262045A1 (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK40009588B (en) Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN101495479A (zh) 咪唑并氮杂环庚烯酮化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251210

R150 Certificate of patent or registration of utility model

Ref document number: 7789483

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150